Cantargia AB: Cantargia advances TRIFOUR trial to randomized stage following promising early safety and efficacy of nadunolimab in triple-negative breast cancer

LUND, Sweden, Feb. 23, 2023 /PRNewswire/ -- Cantargia (Cantargia AB) (NASDAQ Stockholm: CANTA) today reported favorable safety and promising early signs of efficacy following an initial analysis

Related Keywords

Sweden ,Stockholm ,Spain ,Spanish ,Dennis Riedl ,Durani Reynals ,Agostina Stradella ,Prnewswire Cantargia ,Catalan Institute Of Oncology ,Spanish Breast Cancer Group ,Principal Investigator ,Catalan Institute ,Nasdaq Stockholm ,Cantargia ,Advances ,Irifour ,Trial ,Randomized ,Stage ,Following ,Romising ,Early ,Safety ,Efficacy ,Adunolimab ,Triple ,Negative ,Breast ,Dancer ,